FY2026 Earnings Estimate for ARWR Issued By HC Wainwright

Key Points

• HC Wainwright lowered Arrowhead Pharmaceuticals’ FY2026 EPS estimate to a loss of $3.33 per share from $2.68, while maintaining a Buy rating and a $120 price target. The firm projects continued losses through FY2029 before profitability in FY2030.
• Arrowhead reported a quarterly loss of $1.36 per share, missing the $1.23 consensus estimate, although revenue of $75.25 million surpassed expectations and increased 171% year over year.
• Analyst sentiment remains favorable, with nine Buy ratings, three Holds and one Sell, producing a consensus “Moderate Buy” rating and average price target of $97.33.

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) - Stock analysts at HC Wainwright reduced their FY2026 earnings per share estimates for Arrowhead Pharmaceuticals in a report issued on Thursday, August 6th. HC Wainwright analyst P. Trucchio now expects that the biotechnology company will earn ($3.33) per share for the year, down from their previous estimate of ($2.68). HC Wainwright has a "Buy" rating and a $120.00 price objective on the stock. The consensus estimate for Arrowhead Pharmaceuticals' current full-year earnings is ($3.46) per share. HC Wainwright also issued estimates for Arrowhead Pharmaceuticals' Q4 2026 earnings at ($2.74) EPS, Q1 2027 earnings at ($1.42) EPS, Q2 2027 earnings at ($1.64) EPS, Q3 2027 earnings at ($1.65) EPS, Q4 2027 earnings at $0.08 EPS, FY2027 earnings at ($4.61) EPS, FY2028 earnings at ($4.14) EPS, FY2029 earnings at ($1.37) EPS and FY2030 earnings at $5.42 EPS.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last released its earnings results on Tuesday, August 4th. The biotechnology company reported ($1.36) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.23) by ($0.13). The firm had revenue of $75.25 million during the quarter, compared to analysts' expectations of $44.17 million. Arrowhead Pharmaceuticals had a negative return on equity of 60.06% and a negative net margin of 47.79%.The business's quarterly revenue was up 171.0% compared to the same quarter last year. During the same period in the prior year, the business earned ($1.26) earnings per share.

ARWR has been the subject of several other research reports. JPMorgan Chase & Co. lifted their price objective on Arrowhead Pharmaceuticals from $88.00 to $95.00 and gave the stock an "overweight" rating in a report on Friday, July 17th. Stifel Nicolaus assumed coverage on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, July 14th. They set a "buy" rating and a $98.00 target price for the company. Piper Sandler reiterated an "overweight" rating and issued a $126.00 target price (up from $110.00) on shares of Arrowhead Pharmaceuticals in a research note on Thursday, July 23rd. B. Riley Financial lifted their target price on shares of Arrowhead Pharmaceuticals from $101.00 to $123.00 and gave the stock a "buy" rating in a research note on Thursday, July 30th. Finally, Sanford C. Bernstein boosted their price target on shares of Arrowhead Pharmaceuticals from $35.00 to $46.00 and gave the company a "market perform" rating in a research report on Wednesday, May 13th. Nine investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $97.33.

Arrowhead Pharmaceuticals Price Performance

Shares of NASDAQ ARWR opened at $87.65 on Monday. The company has a debt-to-equity ratio of 1.77, a current ratio of 5.90 and a quick ratio of 5.90. The stock has a market capitalization of $12.35 billion, a PE ratio of -38.96 and a beta of 1.27. Arrowhead Pharmaceuticals has a one year low of $15.01 and a one year high of $95.49. The business's fifty day moving average price is $79.97 and its 200-day moving average price is $71.48.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. BlackRock Inc. purchased a new position in Arrowhead Pharmaceuticals during the second quarter worth about $1,208,838,000. Arrowstreet Capital Limited Partnership raised its holdings in shares of Arrowhead Pharmaceuticals by 3,142.5% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 2,081,689 shares of the biotechnology company's stock valued at $71,797,000 after acquiring an additional 2,017,489 shares in the last quarter. Norges Bank purchased a new stake in shares of Arrowhead Pharmaceuticals in the 4th quarter valued at about $113,159,000. Fred Alger Management LLC boosted its position in shares of Arrowhead Pharmaceuticals by 497.4% during the 4th quarter. Fred Alger Management LLC now owns 1,832,997 shares of the biotechnology company's stock valued at $121,693,000 after acquiring an additional 1,526,164 shares during the last quarter. Finally, Renaissance Technologies LLC bought a new stake in shares of Arrowhead Pharmaceuticals during the 1st quarter valued at about $64,988,000. 62.61% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Arrowhead Pharmaceuticals

In other Arrowhead Pharmaceuticals news, Director Hongbo Lu sold 2,970 shares of the firm's stock in a transaction on Tuesday, May 12th. The shares were sold at an average price of $76.88, for a total value of $228,333.60. Following the completion of the transaction, the director directly owned 52,012 shares of the company's stock, valued at $3,998,682.56. This trade represents a 5.40% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 3.60% of the stock is owned by corporate insiders.

Arrowhead Pharmaceuticals News Summary

Here are the key news stories impacting Arrowhead Pharmaceuticals this week:

• Positive Sentiment: Analysts raised Arrowhead’s price target to $120, implying meaningful upside from recent trading levels and signaling confidence in the company’s longer-term pipeline potential. Arrowhead Pharmaceuticals Price Target Raised to $120.00
• Positive Sentiment: Arrowhead Pharmaceuticals received a consensus “Moderate Buy” recommendation, providing additional support for the recent strength in ARWR shares. Arrowhead Pharmaceuticals Receives Consensus Recommendation of Moderate Buy
• Positive Sentiment: Zacks Research raised its FY2026 EPS forecast to a loss of $3.45 per share from a loss of $3.75, while increasing its Q4 forecast to a loss of $1.35 from $1.51. The revisions suggest somewhat improved near-term expectations, though earnings remain negative.
• Neutral Sentiment: HC Wainwright maintained a Buy rating and $120 price target. Its long-range forecast still anticipates a transition to profitability, including projected positive EPS of $5.42 in FY2030. However, the timing and scale of that outlook remain dependent on successful development and commercialization of Arrowhead’s drug candidates.
• Negative Sentiment: HC Wainwright cut EPS estimates across FY2026 through FY2029, including FY2027 to a loss of $4.61 from $3.35 and FY2028 to a loss of $4.14 from $3.12. The reductions point to greater expected losses before profitability and could weigh on investor sentiment.
• Negative Sentiment: The latest quarterly results previously showed a wider-than-expected loss, with EPS of negative $1.36 versus the consensus loss of $1.23, despite revenue substantially exceeding estimates and rising 171% year over year.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company's approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company's pipeline includes multiple candidates in various stages of development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source